Andreas M. Schmitt

2.4k total citations
25 papers, 650 citations indexed

About

Andreas M. Schmitt is a scholar working on Oncology, Molecular Biology and Economics and Econometrics. According to data from OpenAlex, Andreas M. Schmitt has authored 25 papers receiving a total of 650 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Economics and Econometrics. Recurrent topics in Andreas M. Schmitt's work include Cancer Immunotherapy and Biomarkers (8 papers), CAR-T cell therapy research (4 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). Andreas M. Schmitt is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), CAR-T cell therapy research (4 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). Andreas M. Schmitt collaborates with scholars based in Switzerland, United Kingdom and Germany. Andreas M. Schmitt's co-authors include Claudine Seeliger, Jan S. Bauer, Martijn van Griensven, A. Haug, Helen Vester, Lars G. Hemkens, John P. A. Ioannidis, Cathrine Axfors, Viktoria Gloy and Perrine Janiaud and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Andreas M. Schmitt

21 papers receiving 644 citations

Peers

Countries citing papers authored by Andreas M. Schmitt

Since Specialization

Citations

This map shows the geographic impact of Andreas M. Schmitt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas M. Schmitt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas M. Schmitt more than expected).

Fields of papers citing papers by Andreas M. Schmitt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas M. Schmitt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas M. Schmitt. The network helps show where Andreas M. Schmitt may publish in the future.

Co-authorship network of co-authors of Andreas M. Schmitt

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas M. Schmitt. A scholar is included among the top collaborators of Andreas M. Schmitt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas M. Schmitt. Andreas M. Schmitt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Anatomic versus non‐anatomic liver resection for hepatocellular carcinoma—A European multicentre cohort study in cirrhotic and non‐cirrhotic patients 2024 ·Cancer Medicine ·Jasmin Zeindler, (unknown), (unknown), (unknown), (unknown), Andreas M. Schmitt, Simone Muenst, Martin Bolli, Savas D. Soysal, Otto Kollmar	8
2	Dual Immune Checkpoint Inhibition in Melanoma and PD-L1 Expression: The Jury Is Still Out 2024 ·Journal of Clinical Oncology ·Andreas M. Schmitt, James Larkin, Sapna P. Patel	4
3	How have immune checkpoint inhibitors transformed melanoma treatment? 2023 ·Trends in Urology & Men s Health ·Andreas M. Schmitt, James Larkin	0
4	The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020 2023 ·International Journal of Cancer ·Viktoria Gloy, Andreas M. Schmitt, (unknown), Julian Hirt, Cathrine Axfors, (unknown), Tiago Pereira, Clara Locher, (unknown), (unknown), Mark P. Lythgoe, Amanda K. Herbrand, Benjamin Kasenda, Lars G. Hemkens	24
5	The short- and long-term outcome after the surgical management of common bile duct stones in a tertiary referral hospital 2023 ·Langenbeck s Archives of Surgery ·(unknown), (unknown), Jasmin Zeindler, Simone Muenst, Andreas M. Schmitt, Silvio Däster, Martin Bolli, Otto Kollmar, Savas D. Soysal	3
6	Ipilimumab plus nivolumab in patients with symptomatic melanoma brain metastasis requiring corticosteroids 2023 ·European Journal of Cancer ·(unknown), (unknown), (unknown), (unknown), Andrew J.S. Furness, James Larkin, Andreas M. Schmitt	10
7	2286P COVID-19 vaccinations in cancer patients (pts): An individual participant data meta-analysis of the International Consortium on COVID vaccination in cancer 2023 ·Annals of Oncology ·(unknown), Andreas M. Schmitt, Scott T.C. Shepherd, Arkajyoti Bhattacharya, Catherine Bresee, Rudolf S.N. Fehrmann, Sjoukje F. Oosting, Astrid A.M. van der Veldt, Karen L. Reckamp, J.B.A.G. Haanen, Elisabeth G.E. de Vries, Samra Turajlic	1
8	Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA) 2022 ·Cancers ·Markus Joerger, Yannis Metaxas, Khalil Zaman, Olivier Michielin, Nicolas Mach, Adrienne Bettini, Andreas M. Schmitt, Nathan Cantoni, Clemens B. Caspar, (unknown), (unknown), Miklos Pless, Christian Britschgi, Christoph Renner, Dieter Koeberle, Jessica D. Schulz, Christoph Kopp, Stefanie Hayoz, Anastasios Stathis, Roger von Moos	3
9	Management of Toxicity and Side Effects of Systemic Therapy for Renal Cell Carcinoma 2022 ·SHILAP Revista de lepidopterología ·Kate Young, Andreas M. Schmitt, Deborah Mukherji, Lavinia Spain, Manuela Schmidinger, Lisa Pickering	0
10	Characteristics and survival of patients with cancer with intended off-label use—a cohort study 2022 ·BMJ Open ·Andreas M. Schmitt, Martin A. Walter, Amanda K. Herbrand, (unknown), Giusi Moffa, Urban Novak, Lars G. Hemkens, Benjamin Kasenda	1
11	Hitting the sweet spot: optimal use of corticosteroids for immune checkpoint inhibitor side-effects 2022 ·The Lancet Oncology ·Andreas M. Schmitt, Lavinia Spain, James Larkin	6
12	1557O Adaptive immunity to SARS-CoV-2 infection and vaccination in cancer patients: The CAPTURE study 2021 ·Annals of Oncology ·(unknown), Annika Fendler, Lewis Au, Fiona Byrne, Katalin A. Wilkinson, Mary Wu, Andreas M. Schmitt, Nalinie Joharatnam‐Hogan, Benjamin Shum, Lyra Del Rosario, Kim Edmonds, Eleanor Carlyle, Emma Nicholson, Michael Howell, Charles Swanton, Susanne N. Walker, George Kassiotis, Robert J. Wilkinson, James Larkin, Samra Turajlic	10
13	COVID-evidence: a living database of trials on interventions for COVID-19 2020 ·OSF Preprints (OSF Preprints) ·Cathrine Axfors, Andreas M. Schmitt, (unknown), Ramon Saccilotto, Lars G. Hemkens, Perrine Janiaud, Julian Hirt	9
14	Hydroxychloroquine and chloroquine for survival in COVID-19: an international collaborative meta-analysis of randomized trials 2020 ·OSF Preprints (OSF Preprints) ·Perrine Janiaud, David Moher, Lars G. Hemkens, John P. A. Ioannidis, Cathrine Axfors, Janneke van ’t Hooft, (unknown), Andreas M. Schmitt	0
15	Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016 2020 ·JAMA Network Open ·(unknown), Andreas M. Schmitt, Benjamin Speich, Florian Naudet, Arnav Agarwal, Tiago Pereira, Francesco Sclafani, Amanda K. Herbrand, Matthias Briel, Juan Martín-Liberal, Thomas Schmid, Hannah Ewald, John P. A. Ioannidis, Heiner C. Bucher, Benjamin Kasenda, Lars G. Hemkens	60
16	LBA80 Outcome and prognostic factors of SARS CoV-2 infection in cancer patients: A cross-sectional study (SAKK 80/20 CaSA) 2020 ·Annals of Oncology ·Markus Joerger, Yannis Metaxas, Andreas M. Schmitt, Dieter Koeberle, Khalequ Zaman, Daniel Betticher, Nicolas Mach, (unknown), Michael Mark, Ulf Petrausch, Clemens B. Caspar, Christian Britschgi, Christian Taverna, (unknown), Walter Mingrone, Jonathan E. Schulz, Christoph Kopp, Stefanie Hayoz, Anastasios Stathis, Roger von Moos	1
17	Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project 2019 ·ESMO Open ·Amanda K. Herbrand, Andreas M. Schmitt, Matthias Briel, Stefan Diem, Hannah Ewald, (unknown), Markus Joerger, Kimberly A. Mc Cord, Urban Novak, Sirintip Sricharoenchai, Lars G. Hemkens, Benjamin Kasenda	4
18	Rituximab in primary central nervous system lymphoma—A systematic review and meta‐analysis 2019 ·Hematological Oncology ·Andreas M. Schmitt, Amanda K. Herbrand, Christopher P. Fox, Katerina Bakunina, Jacoline E. C. Bromberg, Kate Cwynarski, Jeanette K. Doorduijn, Andrés J.M. Ferreri, Gerald Illerhaus, Samar Issa, Elisabeth Schorb, Emanuele Zucca, Lars G. Hemkens, Stefan Schandelmaier, Benjamin Kasenda	51
19	Five Freely Circulating miRNAs and Bone Tissue miRNAs Are Associated With Osteoporotic Fractures 2014 ·Journal of Bone and Mineral Research ·Claudine Seeliger, (unknown), A. Haug, Helen Vester, Andreas M. Schmitt, Jan S. Bauer, Martijn van Griensven	282
20	The Pseudomonas aeruginosa outer membrane protein I vaccine: immunogenicity and safe administration in man. 1997 ·PubMed ·(unknown), (unknown), (unknown), Andreas M. Schmitt, (unknown), H Domdey	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact